AB Science is a late-clinical-stage French company founded in 2001 by a team of scientists with the goal of developing innovative drugs for high unmet medical needs.
The Company is based in Paris and has been listed on Euronext since 2010 (compartment B, Paris, France).
AB Science has over 100 employees, mostly dedicated to R&D activities.
AB Science is currently developing two main compounds, masitinib, a highly selective tyrosine kinase inhibitor and AB8939, a new generation microtubule destabilizer.
In human medicine, AB Science has a unique indication portfolio with multiple late-stage programs including blockbuster potential and orphan diseases.
Masitinib has already generated positive phase 2B/3 results in Amyotrophic Lateral Sclerosis, Indolent Systemic Mastocytosis, Severe Asthma, Progressive Forms of Multiple Sclerosis, First Line Pancreatic Cancer with Pain, Alzheimer’s Disease and Metastatic Castrate-Resistant Prostate Cancer.
3 Avenue George V, 75008 Paris – France
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.